Session » Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1663

Assessment of Serum Calprotectin and Osteoprotegerin Levels in a Cohort of Spanish Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1673

Characteristic Phenotypes of Peripheral T Cells and Efficacy of Biological Dmards in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1656

Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis

9:00AM-11:00AM: Abstract Number: 1670

Cytokine Expression in Groups of Psoriatic Arthritis Patients Characterised By Specific HLA Genotypes and Clinical Features

9:00AM-11:00AM: Abstract Number: 1667

Diagnostic Value of Anti-CD74 Antibodies in Axial Spondyloarthritis: Results from a Population with Low HLA-B27 Prevalence Background

9:00AM-11:00AM: Abstract Number: 1654

Differential Serum Protein Expression in Groups of Psoriatic Arthritis Patients Characterised By Specific HLA Genotypes and Clinical Features

9:00AM-11:00AM: Abstract Number: 1674

Do TNF Inhibitors Change the Progression of Sacroiliitis?

9:00AM-11:00AM: Abstract Number: 1678

JAK STAT Kinase Cascade Regulates the IL-23/IL-17 Cytokine Axis in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1676

Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1672

Microrna-29a Activation of Canonical Wnt Signaling By Targeting LRP6 in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1666

Micrornas Mir-30b-5p, Mir-34a-5p, and Mir-431-3p Are Highly Expressed in the Plasma of Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1671

Pirfenidone Might Inhibit New Bone Formation in Spondyloarthritis: Proof of Concept Study Using Cell Culture Models

9:00AM-11:00AM: Abstract Number: 1655

Plasma microRNA Expression Profiles in Ankylosing Spondylitis Patients

9:00AM-11:00AM: Abstract Number: 1664

Protein Fingerprinting Screening Specific Proteins in Serum of Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1658

Regulatory Role of the IL-9/IL-9R System on Pannus Formation in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1660

Role of Immune System Cells and Induction of Netosis-Mediated Cell Death in the Development of Atherosclerosis in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1668

Selective Inhibition of Tumor Necrosis Factor-α Receptor 2 (TNFR2) Activity Alleviates Psoriasiform Inflammation in Mouse Models

9:00AM-11:00AM: Abstract Number: 1677

Serum Complement C3 Component As a Potential Disease Activity Marker in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1657

Soluble Biomarkers May Differentiate Psoriatic Arthritis from Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1662

The Association Between Radiologic Progression and Serum Levels of Potential Markers of Bone Formation in Ankylosing Spondylitis Patients

9:00AM-11:00AM: Abstract Number: 1661

Toll-like Receptor 4 Induced IL-20 and IL-24 Stimulate Osteoblast Mineralization and Are Increased in Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1675

Triptolide Inhibits Th17 Differentation By JAK2/STAT3 Signal Pathway in Inflammation of Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1669

Type 3 Innate Lymphoid Cells Numbers in Peripheral Blood Predict Ustekinumab (Stelara) Therapy Responsiveness in Psoriatic Disease Cases with Subclinical Imaging Enthesopathy

9:00AM-11:00AM: Abstract Number: 1665

Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].